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Exposure to the estrogen receptor alpha (ERα) ligand diethylstilbesterol (DES) between neonatal days 2 to 12 induces penile
adipogenesis and adult infertility in rats. The objective of this study was to investigate the in vivo interaction between DES-
activated ERα and the proadipogenic transcription factor peroxisome proliferator-activated receptor gamma (PPARγ). Transcripts
for PPARs α, β,a n dγ and γ1a splice variant were detected in Sprague-Dawley normal rat penis with PPARγ predominating. In
addition, PPARγ1b and PPARγ2 were newly induced by DES. The PPARγ transcripts were signiﬁcantly upregulated with DES
and reduced by antiestrogen ICI 182, 780. At the cellular level, PPARγ protein was detected in urethral transitional epithelium
and stromal, endothelial, neuronal, and smooth muscular cells. Treatment with DES activated ERα and induced adipocyte
diﬀerentiation in corpus cavernosum penis. Those adipocytes exhibited strong nuclear PPARγ expression. These results suggest a
biological overlap between PPARγ and ERα and highlight a mechanism for endocrine disruption.
Copyright © 2008 Mahmoud M. Mansour et al. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
Endocrine disruption, originally limited to steroid receptor
signaling, now extends to include other members of the
48 reported nuclear receptor superfamily [1]. Both perox-
isome proliferator-activated receptor gamma (PPARγ)a n d
estrogen receptor alpha (ERα) are targets for endocrine
disrupting chemicals [2–4]. Recently, Goyal et al. showed
that neonatal exposure of rats to the estrogenic endocrine
disruptor diethylstilbestrol (DES) induced adipogenesis in
penile corpus cavernosum by activation of ERα [5–8]. In this
model of DES-ERα activation, DES exposure at a dose of 0.1
to 0.12mg/kg bw/day, on alternate days, from postnatal days
2 to12, resulted in infertility in 100% of the treated male rats.
Loss of fertility was associated with abnormal accumulation
offatcellsinthecorpuscavernosumpenis,andtheassociated
loss of cavernous spaces apparent as early as postnatal day
18 (reviewed in [9]). It remains unknown, however, whether
this penile ERα-induced adipogenesis is mediated by activa-
tion of a constitutively expressed or DES-induced PPARγ.
Both ERα and PPARγ pathways are implicated in fat
regulation.First,recentﬁndingssuggestthatPPARγ andERα
pathways involve shared coactivators that promote diﬀeren-
tiation of preadipocytes into mature fat cells. For example,
constitutive coactivator of PPARγ (CCPG) is described as a
bona ﬁde coactivator that cross reacts with ERα independent
of its ligand and contains four LXXLL motifs that are
c h a r a c t e r i s t i co fn u c l e a rr e c e p t o rc o a c t i v a t o r s[ 10]. Second,
studies have shown that forced expression of PPARγ2o r
PPARγ1 can trigger the diﬀerentiation of ﬁbroblasts to
adipocytes resulting in the activation of adipocyte-speciﬁc
genes and lipid accumulation [11].2 PPAR Research
The PPAR family consists of three isotypes that include
PPARα (NR1C1), PPARβ (also known as PPARδ,N R 1 C 2 ,
FAAR, or NUC-1), and PPARγ (NR1C3) [12–14]. A nuclear
receptor, PPARγ, is known to play a central role in fat
metabolism and adipocyte diﬀerentiation [15, 16]. The
PPARγ is present in two key isoforms, PPARγ1a n dP P A R γ2.
The two isoforms stem from alternate promoters [17].
Compared to PPARγ1, PPARγ2 has an additional 30 amino
acids at the N-terminal end and is distinctively expressed
in adipose tissue, where it plays a key role in adipogenesis
[18]. These nonsteroidal receptors (i.e., do not mediate
eﬀects of steroids) form part of a class I nuclear hormone
receptor superfamily [19] and function as ligand-activated
transcription factors [20–22].
Each of the three PPAR isotypes is constitutively
expressed in certain reproductive and nonreproductive rat
tissues [23, 24], but their temporal and cell-speciﬁc expres-
sion in penile tissue, with the exception of a limited demon-
stration of PPARγ in penile corporal smooth muscle cells
[25], has not been shown. Further, no speciﬁc link is known
between neonatal activation of ERα and penile PPARγ.
This is important given the expanded deﬁnition of the
term endocrine disruptors to include activation of metabolic
sensorssuchasPPARs.Anumberofﬁndingssuggestinvolve-
mentofPPARsinendocrine disruption eitherthroughdirect
receptor activation or indirectly through crosstalk with other
nuclear receptors. First, in vitro studies demonstrated that
PPARγ and ERα (the iconic receptor involved in endocrine
disruption) are implicated in cross-talk [26–28]. Second,
some endocrine disruptor chemicals, such as monethylhexyl
phthalate (MEHP), a primary metabolite of diethylhexyl
phthalate (DEHP), mediate their toxic eﬀect by PPARγ
activation [29, 30]. Third, several nonbiological xenobiotics
compounds can activate PPARγ. For example, activation of
PPARγ with synthetic PPARγ activators, such as antidiabetic
drugs thiazolidinediones (TZDs), improve insulin sensitivity
but they undesirably increase preadipocyte diﬀerentiation
and white adipose tissue mass [31–33]. Consistent with
this adipogenic eﬀect, reduced PPARγ level, as in mice
with heterozygous (PPARγ+/−) deﬁciency, is associated with
reduced white adipose tissue mass [34].
Findings related to interaction between ERα and PPARγ
intheaforementionedDES-penileratmodelwillilluminatea
potential molecular mechanism by which estrogen exposure
at critical period of development perturbs reproductive
tissues. Therefore, we hypothesize that DES-induced penile
adipogenesis is associated with ERα-mediated activation of
PPARγ. Objectives of this study were to (1) determine
the basal expression of PPARs (α, β,a n dγ) in rat penis
and (2) evaluate the neonatal modulatory eﬀect of ERα-
activator DES on penile PPARγ as a marker of undesirable
adipogenesis.
2. MATERIALS AND METHODS
2.1. Animalsandtreatments
This DES study was performed in collaboration with Dr.
Hari Goyal at Tuskegee University using male pups from
pregnantfemaleSprague-Dawley(SD)rats(HarlanSprague-
Dawley, Indianapolis, Ind, USA). All animal procedures were
approved by Institutional Animal Care and Use Committee
at Tuskegee University. In all experiments, rats were main-
tained using standard housing conditions including constant
temperatureof22◦C,adlibitumwaterandfeeding,and12:12
hours light dark cycle. Two experiments were conducted.
In experiment 1, three groups of male pups (n = 5p e r
group, all were littermates) received subcutaneous injections
of 25μL of olive oil (control), oil containing DES (0.1mg/kg,
Sigma-Aldrich, St. Louis, Miss, USA), or DES plus ICI 182,
780(16.6mg/kg,ICI;TocrisBioscience,Ellisville,Miss,USA)
daily on postnatal day 2 to 6. Rats in experiment 1 were
sacriﬁced at 28 day of age. ICI 182, 780 is a high-aﬃnity
estrogen receptor antagonist (IC50 = 0.29nM) and is also
considered a high-aﬃnity ligand for the membrane estrogen
receptor GPR30 (Tocris Bioscience). In experiment 2, two
groups of male pups (n = 4 per group) received DES
(1mg/kg) or olive oil (control) every other day for 6 days
starting at postnatal day 2. Penile tissues were collected from
rats sacriﬁced at 120 days of age (adulthood). Small sections
of the penile shaft tissue from each rat in experiment 1 and
2 were ﬁxed overnight in 4% paraformaldehyde for IHC
or fat staining, and the remainder of the shaft tissue was
frozen in liquid nitrogen and stored at −80◦Cf o rR N A
extraction and PCR analysis. The doses used for end-point
evaluation at 28 and 120 days post-treatment were based
on previous publications from our group that showed DES
prenatal exposure (between postnatal days 2 to12) at a dose
rangeof0.1to0.12mg/kg/day,orhigher(1mg/kg/day)result
in similar abnormal penile development and adipogenesis
[5, 8].
2.2. TotalRNAisolation
Total RNA was isolated from the body of the penis using
TRIZOL reagent (Invitrogen-Life Technologies Inc., Carls-
bad, Calif, USA), according to the manufacturer’s protocol.
RNA concentrations were estimated at 260nm and the ratio
of 260/280 was determined using UV spectrophotometry
(DU640, Beckman Coulter Fullerton, Calif, USA). The
integrity of each RNA sample, indicated by the presence
of intact 28S and 18S ribosomal RNA, was veriﬁed by
denaturing agarose gel electrophoresis. RNA samples were
treated with DNase (Ambion Inc.) to remove possible
genomic DNA contamination. Samples with 260/280 ratio of
≥1.8 were used.
2.3. Conventionalend-pointandreal-timePCR
Expression of mRNA for PPAR (α, β,a n dγ)i s o t y p e sw a s
initiallydeterminedbyconventionalend-pointRT-PCRwith
primers designed using primer quest software and synthe-
sized by Integrated DNA Technology (IDT Inc, Coralville,
Iowa, USA) from previously published rat sequences (see
Table 1). Subsequently, semiquantitative RT-PCR for coam-
pliﬁcation of PPARs and S-15 (known as Rig; small subunit
ribosomal protein used as a house keeping gene) was
performed to determine the relative expression levels ofMahmoud M. Mansour et al. 3
Table 1: PCR primer sets, sequence, product size (bp), nucleotide (nt) location, and GenBank accession numbers for rat PPARs used in this
study. Note that a common antisense oligoprimer (sequence in bold) was used for PPARγ1a, PPARγ1b, and PPARγ2.
Product/ Sense primer Antisense primer Product size nt
accession# (bp) location
PPARα 5-TTG TGA CTG GTC AAG CTC AGG ACA-3 5-TCG TAC GCC AGC TTT AGC CGA ATA-3 492 296–787
NM013196
PPARβ 5-TAA CGC ACC CTT CAT CAT CCA CGA-3 5-TTG ACA GCA AAC TCG AAC TTG GGC-3 390 873–1262
U40064
PPARγ 5-TCT CCA GCA TTT CTG CTC CAC ACT-3 5-ATA CAA ATG CTT TGC CAG GGC TCG-3 533 257–789
NM013124
PPARγ1a 5-CTG ACG AGG TCT CTC TC G GCT G-3 5-AGC AAGGCACTT CTGAA ACCGA-3 658 21–679
AF246458
PPARγ1b 5-CAG CGC TAA ATT CAT CTT AAC T-3 5-AGC AAG GCA CTT CTG AA A CCG A-3 618 21–639
AF246457
PPARγ2
5-GAG CAT GGT GCC TTC GCT GA-3 5-AGC AAG GCA CTT CTG AA A CCG A-3
563
37–600
AB019561 85–648
AF156666 86–649
Y12882
PPARγ/ERα (primers for real-time PCR were obtained from Superarray Inc) 190/179 [PPARγ/ERα]
NM013124
[PPARγ]
(Sequence are not disclosed by the Company) respectively
NM012689
[ERα]
Gapdh
5-ATG ATT CTA CCC ACG GCA AG-3 5-CTG GAA GAT GGT GAT G CGT T-3 89
71–159
DQ403053 184–272
BC087743 216–304
BC059110
Rig/S15
(Ambion) 5-TTC CGC AAG TTC ACC TAC C-3 5-CGG GGC CGG CCA TGC T TTA CG-3 361 74–433
BC105810
PPAR isotypes. Veriﬁcation of accurate PCR products was
conﬁrmed by determination of the expected size of PCR
bands and by sequence analysis of generated amplicons
at Auburn University sequencing facility. The resulting
sequences for the three PPAR isotypes were matched with
previously published rat sequences in GenBank (accession
number NM013196, U40064,a n dNM013124 for PPARα,
PPARβ,a n dP P A R γ, resp.) using Chromas 2.31 software
(Technelysium Pty ltd, Tewantin Qld 4565, Australia).
PPARγ splice variants or subtypes were identiﬁed using
speciﬁc primers designed for rat PPARγ1a and PPARγ1b
synthesized by IDT Inc. (Table 1). Liver and white adipose
tissues from adult Sprague-Dawley rats in experiment 2
were used as positive controls for PPARγ1[ 35]a n dP P A R γ2
[18], respectively. The ampliﬁcation protocol was as follows:
initial cycle for 3 minutes at 95◦C, and 30 cycles each at
(95◦C for 30 seconds, 55◦C for 30 seconds, and 72◦Cf o r
30 seconds) followed by a ﬁnal extension cycle at 72◦Cf o r
7 minutes. PCR reactions were performed on a Robocycler
(Stratagene Inc, La Jolla, Calif, USA) and products were
analyzed electrophoretically on 2% (w/v) agarose gels. The
intensity of the PCR bands was determined using Fluor-
S multi-imaging analysis system (Bio-Rad, Hercules, Calif,
USA).LevelofmRNAforPPARswasnormalizedtothelevels
of S-15 housekeeping gene.
Quantitative real-time PCR (Bio-Rad, MyiQTM)f o r
determination of expression levels of PPARγ and ERα
mRNA was performed in 25-μL reaction mixture containing
12.5μLRT
2 real-time SYBR/Fluorescein Green PCR master
mix, 1μL ﬁrst strand cDNA, 1μLRT
2 validated PCR primer
set for PPARγ or ERα (Super Array Bioscience Corporation,
Frederic, Md, USA), and 10.5μLP C R - g r a d ew a t e r( A m b i o n
Inc). Samples were run in 96-well PCR plates (Bio-Rad,
Hercules, Calif, USA) in duplicates, and the results were
normalizedtoGAPDH(seeprimersetinTable 1)expression.
The ampliﬁcation protocol was set at 95◦Cf o r1 5m i n u t e s
for one cycle, and 40 cycles each at (95◦C for 30 seconds,
55◦C for 30 seconds, and 72◦C for 30 seconds) followed
by melting curve determination between 55◦Ca n d9 5 ◦Ct o
ensure detection of a single PCR product. Template RNA
from rat white adipose tissue and penis were used for
determination of ampliﬁcation eﬃciencies for (ERα/PPARγ)
targets and GAPDH by generating standard curves. Curves
were generated by using serial 10-fold dilutions total RNA4 PPAR Research
and plotting the log dilution against CT (threshold cycle)
value obtained for each dilution. The Pearson’s correlation
coeﬃcient (r) value for each generated standard curve
was ≥0.98, and the calculated ampliﬁcation eﬃciency was
between 98.5 to 99%.
2.4. Immunohistochemistry(IHC)
Immunolocalization of PPARγ in penile tissue was per-
formed using mouse anti-PPARγ IgG1 monoclonal antibody
(sc7273, Santa Cruz Biotechnology Inc, Santa Cruz, Calif,
USA) raised against a C-terminus sequence of human and
mouse PPARγ (similar to the corresponding rat sequence).
The antibody detects PPARγ1, PPARγ2 and, to a lesser
extent, PPARα and PPARβ of rat, mouse, and human by IHC
using paraplast-embedded tissues. Approximately 5-mm-
long penis sections from the middle of the body of the penis
were ﬁxed in 4% paraformaldehyde for 48 hours, embedded
in Paraplast (Sigma-Aldrich), and cut at 5-μm thickness
[7]. Mounted penis sections were deparaﬃnized in Hemo-
D (Scientiﬁc Safety Solvents, Keller, Tex, USA) and hydrated
to distilled water (dH2O). The slides were transferred to a
r a c ka n dp l a c e di n1Lo f1 0m Ms o d i u mc i t r a t e( p H6 . 0 ) .
The beaker was placed on a hot plate, allowed to come to a
boil and tissues were boiled for 20 minutes. When the citrate
solution cooled to near room temperature (RT), the slides
were transferred to a glass staining dish and equilibrated in
phosphate buﬀered saline (PBS) (Sigma-Aldrich, ST Louis,
Miss, USA). After 20 minutes incubation in blocker (5%
normal goat serum, Sigma-Aldrich) and 2.5% BSA (Sigma)
in PBS, slides were washed brieﬂy in PBS. Anti-PPARγ,
diluted 1:20 in blocker, was applied and the sections were
left to incubate overnight at RT. Next day, slides were washed
3x in PBS, 3 minutes each, and tissues were incubated
with Alexa 488-conjugated goat antimouse IgG (Molecular
Probes, Eugene, Ore, USA) for 1 hour at RT. After washing
two times in PBS, 3 minutes each, slides were mounted with
VectaShield (Vector Laboratories, Burlingame, Calif, USA),
and the coverslips were sealed. The sections were examined
using a Nikon TE2000E microscope and digital images were
generated using an attached Retiga EX CCD digital camera
(Q Imaging, Burnaby, BC, Canada). Penile tissue sections
from all 28-day treated rats were examined. Representative
micrographs from diﬀerent penile histological structures
were shown for untreated control rats, and for rats treated
with DES or DES + ICI.
2.5. Fatstaining
Histochemical demonstration of fat was performed as pre-
viously described [7]. Brieﬂy, tissue sections from penile
body, approximately 5mm-long, were ﬁxed for 24 hours
in 4% formaldehyde, followed by en bloc staining of fat
for 8 hours with 1% osmium tetroxide dissolved in 2.5%
potassium dichromate solution. Specimens were then pro-
cessed for paraplast embedding and cut at 5-μm thickness.
Deparaﬃnized sections were examined for black staining
indicative of fat cells using light microscopy.
2.6. Statisticalanalyses
Analysis of real-time PCR data for relative gene expression
level(foldchangeoftargetrelativetocontrol)wasperformed
using a modiﬁcation of the delta delta Ct method (ΔΔ CT)
as described previously [36]. Statistical diﬀerences between
treatmentgroupswereperformedusingSigma Statstatistical
software (Jandel Scientiﬁc, Chicago, Ill, USA). Δ CT for
real-time PCR data [37], and intensity values (for semi-
quantitativeRT-PCRdata)weresubjectedtoanalysesofvari-
ance. Experimental groups with means signiﬁcantly diﬀerent
(P<. 05) from controls were identiﬁed using Holm-Sidak
and Tukey tests. When data were not distributed normally,
or heterogeneity of variance was identiﬁed, analyses were
performed on transformed or ranked data.
3. RESULTS
3.1. DetectionandsequenceanalysisofPPARand
ERαtranscriptsinthebodyofthepenis
Primer sets used in this study are shown in Table 1.
Transcripts for three PPAR isoforms (α, β,a n dγ)w e r e
detected, albeit at diﬀerent levels, in penile tissue from
normal control adult (120 days) rats (Figure 1, parts A1 and
A2). Semiquantitative RT-PCR analysis of PPARs indicated
predominant expression of PPARγ mRNA when compared
with PPAR (α and β)i s o f o r m s( Figure 1(B)). Sequence
analysis and alignment with published sequence data con-
ﬁrmed the identity of all three PPAR isoforms. Treatment
with DES induced over three-fold-increase (3.38) in ERα
transcripts in 28-day-old rats compared to over two-fold-
increase (2.5) in 120-day-old adult rats when each age
group was compared with its respective untreated controls
(Figure 2). Similarly, DES induced slightly over seven-fold-
increase (7.1) in PPARγ transcription level in 28-day-old
rats compared with over six-fold-increase (6.8) in 120-
day-old adult rats (Figure 3). The upregulation of PPARγ
expression by DES in 28-day-old rats was abrogated when
rats were cotreated with DES and ICI 182, 780 (Figure 4).
The diﬀerences in the transcriptional level of penile ERα and
PPARγ between the DES-treated rat groups (28 versus 120-
day-old rats) were not signiﬁcantly diﬀerent. Because of the
relatively high expression of penile PPARγ in the 28-day-old
rats subsequent studies for determination of splice variants
and PPARγ protein expression were performed in the 28-
day-old rats.
3.2. DetectionofPPARγ splicevariants
andreal-timePCRdata
In order to determine which PPARγ splice variant is
expressed in the body of normal and DES-treated rats,
primers (Table 1) were designed to amplify the two known
rat PPARγ1a and PPARγ1b splice variants using conven-
tional end-point RT-PCR. Splice variant analyses revealed
expression of PPARγ1a in normal 28-day-old rat penis.
However, in addition to PPARγ1a, PPARγ1b and PPARγ2
were newly induced by DES treatment (Figure 5).Mahmoud M. Mansour et al. 5
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Figure 1: (A1) and (A2) RT-PCR ampliﬁcation of three PPARs
(α, β,a n dγ) from the body of the penis of three (1, 2, and 3)
normaladult(120days)controlrats.(A1)Showscoampliﬁcationof
PPARs(α,β,andγ (upperbands)andS15(smallribosomalsubunit
protein as housekeeping gene, lower bands) in two representative
rats (1 and 2). PCR markers were included in lane 1. Expected band
sizes for S-15, PPARα,P P A R β,a n dP P A R γ were 361, 492, 390, and
533bp, respectively. Identities of amplicons were further conﬁrmed
by sequence analysis (see Section 2). Note that the ampilicons for
PPARβ and S15 in lane 5 and 6 were overlapped (compare run for
PPARα,P P A R β,a n dP P A R γ without S15 shown for rat 3 in (A2).
In all rats note the predominant expression of PPARγ.1 5μLP C R
products were loaded per each lane. (B) Graphic representation
of signal intensity for PPARs showing predominant expression
of PPARγ. Transcript levels were normalized to the levels of S15
housekeeping gene. To calculate the intensity for PPARβ the mean
intensity of S-15 in lanes 2, 3, 8, and 9 in Figure (A1) was subtracted
from the combined intensity of PPARβ + S15 in lanes 5 and 6 to
obtain the intensity of penile PPARβ for rat 1 and 2, respectively.
∗P<. 05.
3.3. Immunohistochemistryandfatstaining
Immunohistochemistry results revealed PPARγ protein
localization in transitional epithelium of the urethra, and the
surrounding corpus spongiosum penis. It is also expressed
in stromal, endothelial, neuronal, and smooth muscular cells
of the cavernous sinuses located in the corpus cavernousm
region of normal 28-day-old rat penis (Figures 6(a) and
6(b)). Treatment with DES induced a strong staining inten-
sity for PPARγ protein in the peripherally located nuclei of
newlyinducedadipocytes(Figure 6(a),Panel(c)withamag-
niﬁed inset-box view in C2). PPARγ immunostaining was
markedly reduced by ICI 182,780 treatment (Figure 6(b)). In
unstained penile sections from 28-day-old and adult DES-
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Figure 2: Real-time PCR showing 3.38 and 2.5 fold increase in
ERα mRNA in penile tissue of 28-day-old (DES-28 d) and adult
rats (DES-Adult) neonatally treated with DES, respectively. Fold
change was calculated relative to respective controls (CONT-28 d
and CONT-Adult). Data (n = 4-5) are expressed as mean ±SE.
∗P<. 05.
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Figure 3: Real-time PCR showing 7.1 and 6.8 fold increase in
PPARγ mRNA in penile tissue of 28-day-old (DES-28 d) and adult
rats (DES-Adult) neonatally treated with DES, respectively. Fold
change was calculated relative to respective controls (CONT-28 d
and CONT-Adult). Data (n = 4-5) are expressed as mean ±SE.
∗P<. 01.
treated rats, the new adipocytes were seen as empty spaces
similar to fat cells and were speciﬁcally localized in the
corpus cavernosum region of the penis (Figure 7,p a n e l s( b )
and (d)). In addition, staining with 1% osmium tetroxide
conﬁrmed that the empty spaces were cluster of fat cells
(stained as black granules in Figure 7, panels (c) and (e)). No
fat cells were seen in penile sections from rats treated with
D E S+I C I( Figure 7, panels (f) and (g)).
4. DISCUSSION
This study demonstrated that three PPAR transcripts (α, β,
and γ) are constitutively coexpressed in normal rat penis6 PPAR Research
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Figure 4: Real-time PCR data showing attenuation of the eﬀect of
DESonPPARγ mRNAbyERblockerICI182,780in28-day-oldrats
treated neonatally with either 25μLo fo l i v eo i l( C O N T - 2 8d ) ,o i l
containing DES (DES-28 d; 0.1mg/kg bw), or DES plus ICI (DES +
ICI;16.6mg/kg).ICItreatmentsigniﬁcantlyinhibitedDES-induced
PPARγ mRNA [DES-28 d versus DES + ICI]. Comparison between
control and DES treated rats showed 7.1 fold increase in expression
[CONT-28 d versus DES-28 d]. Letter [a] indicates no signiﬁcant
diﬀerences between CONT-28 d and DES + ICI. Data (n = 5) are
expressed as mean ±SE. ∗P<. 05.
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Figure 5: RT-PCR ampliﬁcation of PPARγ (γ, γ1a, γ1b, and γ2)
splice variants in the body of the penis (P) of control (lanes, 2–5)
and DES-treated (lanes, 7–10) 28-day-old rats. Lanes 12–15 were
ampliﬁcation products from RNA template obtained from rat liver
(L) (used as positive control for PPARγ1b). Lanes 16–19 were RNA
template from rat white adipose tissue (F) (used as positive control
for PPARγ1a and PPARγ2). Note that only PPARγ and PPARγ1a
were detected in (P) of normal rats. In contrast, in DES-treated
rats enhanced expression of all PPARγ splice variants can be noted.
In addition to PPARγ and PPARγ1 ae x p r e s s i o n( s e e ni nn o r m a l
rats), PPARγ1b and PPARγ2 were induced by DES-treatment. As
expected, PPARγ1b and PPARγ2 were strongly expressed in (L)a n d
(F), respectively. S-15 (S, lane 20) is a housekeeping gene ampliﬁed
from (P) as control for RT-PCR conditions. The expected amplicon
sizes for S, PPARγ1a, PPARγ1b, PPARγ2, and PPARγ are 361, 658,
618, 563, and 533bp, respectively.
with PPARγ as the predominant isotype. In addition, it
established that some ERα synthetic ligands, such as DES,
can activate PPARγ subtypes when administered at early
perinatal days. Further, upregulation of ERα by DES was
associated with a corresponding increase in PPARγ suggest-
ing a synergistic interaction between the two receptors.
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Figure 6: (a) Representative immunohistochemical staining for
PPARγ protein in the body of the penis of 28-day-old DES-treated
(A), (B), and (C) and control untreated rats (D), (E), and (F). Note
that PPARγ protein is expressed in DES-treated (DES-28 d) and
normal rats (CONT-28 d) with increased intensity and fat cells in
DES-treated rats (see panel (C)). Note expression in transitional
epithelium of the penile urethra (PU) and the surrounding corpus
spongiousm (CS) in (A) and (D) and in the endothelium of blood
v e s s e l sa n ds m o o t hm u s c l ec e l l si nt h ed o r s a la r t e r y( a )a n dv e i n
(v), and in nerve ﬁbers of the dorsal nerve (n) of the penis (B)
and (E). Similar staining intensity can be seen in the endothelium
and smooth muscles of the vascular lacunae (Vl) in the corpus
cavernosum penis (CC) in control normal rats (F). Note one
contrasting diﬀerence is that the cavernous spaces in DES-treated
rats in panel (C) are replaced with fat cells (Fc) that show increased
staining intensity in the cell nucleus located at cell periphery. Panels
(C2) and (F2) show a closer view of area outlined by insert box.
Controlsections(minusprimaryantibody)wereinpanels(G),(H),
and (I). Scale bar = 30μm. (b) IHC staining for PPARγ protein was
signiﬁcantly reduced by ICI 182, 780 treatment [compare staining
in panels (J) and (M) with (L) and (N)]. Panel (P) is a negative
control (minus primary antibody). Scale bar 30μm.Mahmoud M. Mansour et al. 7
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Figure 7: Micrograph sections from penile body of normal rat (a)
and rats treated neonatally with DES (b)–(e) or DES + ICI (f)-
(g). Panel (a) was from a normal adult rat stained with H and E
for demonstration of normal histological structures of the penis (a:
dorsal artery; v: dorsal vein; CC: corpus cavernosum; CS: corpus
spongiosum;PU:penileurethra;TA:Tunicaalbuginea).Panels((b),
unstained)and((c),stainedforfatwith1%osmiumtetroxide)were
from a 28-day-old rat. Panels ((d), unstained) and ((e), stained
for fat with 1% osmium tetroxide and presented as a magniﬁed
view of CC and CS regions) were from adult rat (120 days) treated
neonatally with DES. Note the empty appearing spaces of fat cells in
CC regions in unstained sections (panels (b) and (d)). In sections
stained with 1% osmium tetroxide (to conﬁrm presence of fat)
fat cells appear as black granules, ∗. Panels ((f), unstained) and
((g), stained with 1% osmium tetroxide) were from a 28-day-old
rat treated neonatally with DES + ICI. Note the absence of empty
appearing fat cells and lack of fat staining in CC region. Sections
from these rats were used for immunolocalization of PPARγ in
Figure 6 parts (a) & (b). Scale bars = 30 (E) and 200μmi no t h e r
panels.
Previous studies that used in situ hybridization to
determine the distribution of PPARs in rat tissues, including
reproductive organs, showed expression of PPARα and
PPARβ in somatic (Sertoli and Leydig) and in germ cells
of the testis, but did not address expression of these two
receptors in penile tissue [23, 24]. The role of PPARα and
PPARβ in the testis, however, remains unknown. Detailed
study addressing expression of PPARγ isotypes in penile
tissue is also lacking, with the exception of a study that
showed limited penile PPARγ expression in corporal smooth
muscle cells [25].
In this study, PPARγ and PPARγ1a were detected in nor-
mal rat penis. However, DES as ERα activator distinctively
induced expression of PPARγ1b and PPARγ2 splice variants
that were not present in control untreated penile tissue.
The induction of splice variant PPARγ1b is in agreement
with previous in vitro studies that demonstrated activation
of PPARγ1 by the endocrine disruptor monoethyl-hexyl-
phthalate in C2C12 mouse skeletal muscle cell line [2],
and with MCF-7 breast cancer cells stimulated with E2,
the natural ERα ligand [38]. Further, the induction of
PPARγ2concurswithincreasedadipogenesisobservedinthe
corpus cavernousm penis as PPARγ2 is considered a unique
marker for mature adipocytes, and its forced induction is
associated with terminal diﬀerentiation of preadipocytes or
ﬁbroblast cells to functional mature adipocytes [11, 22]. The
upregulation of PPARγ was abrogated by coadministration
of the type-II antiestrogen ICI 182,780, indicating that DES
eﬀects were mediated, at least in part, via the estrogen
receptor system. It is possible, however, that ICI may have
directly repressed activation of PPARγ as ICI was previously
shown to inhibit the action of the selective PPARγ agonist
BRL 48, 482 in MDA-MB 231 breast cancer cell culture in
the absence of ER [38].
One important diﬀerence between this study and previ-
ous in vitro studies that addressed signal cross-talk between
PPARγ and ERα using MCF-7 cells [38–40] is that the
activation of ERα by DES in our study is associated with
selective induction of PPARγ1b and PPARγ2. This unique
eﬀect resulted in generation of de novo adipocytes that
provide direct functional proof for PPARγ2 induction. In
contrast to our study, activated ERα by E2 lowers both
basal and ligand-stimulated PPARγ-mediated gene reporter
activity in MCF-7 cancer cell culture [38]. Likewise, acti-
vation of PPARγ in MCF-7 cell culture with the natural
PPARγ ligandcyclopentenone15-deoxy-Δ12,14 prostaglandin
J2 (15d-PGJ2) inhibited estrogen-responsive elements [40].
Consequently, the MCF-7 cell culture studies suggest that
ERα and PPARγ negatively regulate each other. The reason
for the diﬀerence between our study and the aforementioned
in vitro data could be related to diﬀerences between in vitro
and in vivo milieu or to the deletional mutants used in
the in vitro studies compared with the in vivo wild type
receptors in our study. Another reason for the disagreement
could be due to diﬀerences in coactivators and corepressors
presentinMCF-7andpeniletissuecellsormoreimportantly
to diﬀerences in the ligands used. One plausible hypoth-
esis, however, for the increased transcriptional activation
of PPARγ1b and PPARγ2 by DES-activated ERα is that
exposure of rats to DES at a critical neonatal period of
days 1 to 12 is uniquely associated with reprogramming of
penile stromal or preadipocytes to mature adipocytes [5–8].
In support of this concept, it is known that postnatal days 1
to 5 in rodents coincide with a period for reproductive tract
and adipocyte diﬀerentiation [41]. Further, data from other
laboratories indicated that neonatal exposure of rodents to
DESisassociatedwithincreasedwholebodyfatatadulthood8 PPAR Research
[42]. This novel adipogenic eﬀe c to fD E Sw a sp r o p o s e da sa
model for the study of what is called developmental obesity
mediated by early exposure to endocrine disruptors [43].
The molecular mechanism involved in DES-ERα-PPARγ
transactivation could be related to two factors. First,
activated-ERα could directly bind to PPAR response ele-
ments (PPREs) because the two receptors share the capacity
to bind to the AGGTCA half-sites consensus sequences con-
tained as palindrome or direct repeat in estrogen response
elements(EREs)andPPREsequences,respectively[44].This
mechanism could result in bidirectional activation of shared
target sequences between ERα and PPARγ depending on
activatedreceptorinvolved.Second,itisknownthatestrogen
could induce enzymatic conversion of prostaglandin D2
(PGD2) and the endogenous metabolites of the latter can
directly activate PPARγ [45]. The latter eﬀect, however, was
not associated with induced PPARγ mRNA [46] suggesting
that the ﬁrst mechanism could be in play in our study.
The strong PPARγ protein expression in normal tran-
sitional epithelium of the urethra and the dorsal artery
and vein of the penis indicates possible physiological role
for PPARγ in the penis vasculature and the urothelium
of the urinary tract. Although this study did not address
functionality of PPARγ in the penis, current evidence
suggests that its constitutive expression in some tissues is
linked to eicosanoids and prostaglandins (PGs) actions [47,
48]. In this regard, the terminal metabolite of the J series of
PG, 15d-PGJ2, is considered the natural activator of PPARγ
[48]. Sources of penile PGs could include synthesis by local
penile cells and/or cells of the renal medulla where PGs can
be transported via the ureter and pelvic urethra to the penis
[49]. Among other functions, PGs are important mediators
of inﬂammation, vascular homoeostasis, and pain all of
which may be relevant to the pathophysiology of the penis.
Staining with osmium conﬁrmed the presence of new
lipid-laden adipocytes in penile tissues of DES-treated rats.
Previously, our group showed that Sprague-Dawley rats
treated neonatally with DES accumulated fat in the corpus
cavernous penis [5–8] just as observed for the rats in
the present study. The histological demonstration of DES-
induced lipid buildup in the corpus cavernosum penis
concurs with the newly induced adipocyte marker PPARγ2
detected with RT-PCR.
In penile tissue direct pharmacological activation of
PPARγ by the antidiabetic TZD pioglitazone reportedly
blocked corporal veno-occlusive dysfunction in rat model
of type 2 diabetes mellitus [25]. However, this eﬀect was
associated with fat buildup suggesting that direct activation
of penile PPARγ by TZDs or indirectly by ERα ligands, as in
this study, could be a potential pathway for development of
undesirableadipogenesis.Inconclusion,PPARsarecurrently
considered potential drug targets for diverse conditions
including, vascular homoeostasis, diabetes mellitus, hyper-
lipidemia,inﬂammation,cancer,andinfertility[50–54].This
study furthers our knowledge of mechanisms of endocrine
disruption mediated by PPARγ in male subjects. The ERα-
PPARγ signal pathway activation by DES is analogous in
some way to mechanisms postulated for endocrine disruptor
MEHP and other phthalates esters and organotins which
directly activates PPARγ and promotes adipogenesis in cell
culture models [2, 3, 55].
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